Alliance for Artificial Intelligence in Healthcare Opens NYSE to Celebrate AI Appreciation Day
NEW YORK CITY – 14 JULY 2023 – Alliance for Artificial Intelligence in Healthcare (AAIH), a 501(c)(4) non-profit advocacy and educational organization dedicated to promoting the development and implementation of AI in healthcare, will ring the opening bell for the New York Stock Exchange (NYSE) today to celebrate Artificial Intelligence Appreciation Day. AAIH Executive Officers Mustaqhusain Kazi (Chairperson of AAIH, Global Head of Informatics Strategy and Digital Innovation, Roche/Genentech), Stacie Calad-Thomson (Vice-Chairperson of AAIH, Chief Strategy Officer and Head of Drug Discovery, BioSymetrics), James Zanewicz (Treasurer of AAIH, Chief Business Officer, Tulane University School of Medicine), Maria Luisa Pineda, Ph.D., (Secretary of AAIH, Chief Executive Officer, Envisagenics) and Elaine Hamm, Ph.D., (Executive Director, Alliance for AI in Healthcare) will open trading alongside other members of AAIH’s board of directors.
“Artificial intelligence has demonstrated its potential to substantially impact the lives of patients today and will continue to evolve to transform drug R&D, drive equitable healthcare, and deliver better outcomes for patients,” said Mr. Kazi. “The Alliance for Artificial Intelligence in Healthcare is committed to working across the global spectrum – from private companies to academia to regulators – to ensure this game-changing technology is responsibly adopted and implemented in life science and healthcare ecosystems worldwide. We thank the NYSE for recognizing our efforts and continued progress in this space.”
AAIH works globally with academia, research institutions, government NGOs, and key opinion leaders to address critical challenges and opportunities surrounding the adoption of AI in healthcare. AAIH operates through its standing committees to address three key areas: data quality, data access, including social equity and fairness education, and regulatory affairs – working with government stakeholders, including the U.S. Food & Drug Administration (FDA), Health Canada, and the European Medicines Agency (EMA).
Launched in January 2019, the organization has grown from 22 founding members to more than 50 companies representing the entire healthcare and life science spectrum, from drug discovery and clinical development to medical devices and AI-enabled diagnostics. With a common goal of recognizing the potential for AI and machine learning in healthcare to improve the quality of care significantly, these companies work together to establish responsible, ethical, and reasonable standards for its development in the industry.
About Alliance for Artificial Intelligence in Healthcare
The Alliance for AI in Healthcare (AAIH) is a coalition of technology developers, pharmaceutical companies, and research organizations who have expressed the common goal of realizing the potential for AI and machine learning in healthcare to improve the quality of care significantly, but who also recognize the need to address substantial industry challenges. By convening stakeholders to present a unified voice, we are working to establish responsible, ethical, and reasonable standards for developing and implementing AI in healthcare. The AAIH brings together industry, academia, research institutions, government NGOs, key opinion leaders, and other international stakeholders to develop appropriate regulatory principles. By engaging with a wide array of participants across the healthcare spectrum, the AAIH works to actualize the promise of artificial intelligence in medicine, thereby improving patients’ lives and creating more efficient, sustainable, and accessible healthcare systems. For more information, please visit www.theaaih.org
